The Valuation Epidemic: How the Unicorn went from "Rare" to Rampant
In 2013 there were 39 unicorns. Today there are over 1,300. But how many of them justify their immense valuations?
13 min read

Co-founder & Head of Private Markets
LSE BSc Finance
In 2013 there were 39 unicorns. Today there are over 1,300. But how many of them justify their immense valuations?
Martin Moscoso Lapiana with Oscar McGuinness13 min read
The London discount looked like the reason UK companies keep being bought. It was really the lender's underwriting policy, and that sets the ceiling regardless of where the shares trade.
Abir Ghosh Biswas with Oscar McGuinness7 min read
Private equity is quietly rewriting football-club ownership. Chelsea and AC Milan offer two versions of the same wager, and raise the question of whether financial discipline and success on the pitch can ever sit comfortably together.
Raheel Bhuiya with Oscar McGuinness7 min read
Big Pharma is acquiring earlier and accepting greater scientific risk for unproven drugs. The driver is not confidence in the science but the fear of a rival securing the next blockbuster first, as a $300bn patent cliff bears down on the industry.
Abdul Wasey Bhatti with Oscar McGuinness and Jack Childs8 min read
A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation.
Abdul Wasey Bhatti with Oscar McGuinness and Jack Childs4 min read
EQT needed four bids to take Intertek private, and the sequence reveals less about price than about who now sets the value of a FTSE 100 company, and why London keeps losing profitable firms to private buyers.
Abir Ghosh Biswas with Oscar McGuinness6 min read
Vertex's $10 billion acquisition of Crinetics is about far more than adding another drug to its portfolio. It is a strategic bet on an endocrinology platform that could fuel the company's next phase of growth.
Abdul Wasey Bhatti with Oscar McGuinness6 min read
As NHS waiting lists for autism assessments pass 200,000, private capital is flowing into neurodiversity services – forcing the question of whether profit and patient care can ever be aligned.
Abdul Wasey Bhatti with Oscar McGuinness and Jack Childs8 min read
A single FDA reversal sent Regenxbio's shares soaring and reignited optimism across gene therapy - but one favourable decision cannot solve the commercial challenges that pushed the industry into crisis.
Abdul Wasey Bhatti with Jack Childs and Oscar McGuinness6 min read
Novo Nordisk and Eli Lilly have proven GLP-1 drugs can deliver surgery-level weight loss - but with patients regaining much of it after stopping, the market's real value may depend on long-term adherence rather than who wins on efficacy.
Abdul Wasey Bhatti with Oscar McGuinness and Rohan Talwar5 min read
As AI clouds software valuations, private equity is pivoting towards healthcare – a sector whose demand is underpinned by demographics and disease burden that can be forecasted decades ahead.
Abdul Wasey Bhatti with Oscar McGuinness6 min read
Goldman's near miss looked like good news. It was really a warning about everything else.
Abir Ghosh Biswas with Oscar McGuinness and Jack Childs5 min read
A Connecticut credit firm is lending millions against World Cup resale tickets, betting the markup holds. The trade exposes a wider story about how Wall Street is learning to finance scarcity.
Sonal Weerasekera with Jack Childs and Oscar McGuinness8 min read
From Blackstone's bid for Senior plc to the largest LBO in history and a regulatory clash threatening the private credit ratings ecosystem, this week laid bare the tensions running through global private capital markets.
Sonal Weerasekera with Jack Childs and Oscar McGuinness7 min read
Record unsold assets, zombie funds, and pension pain. Why the private equity industry is at a structural turning point.
Alexander Eklund with Jack Childs and Oscar McGuinness12 min read
Retail investors are pulling billions, insiders say defaults are already here, and banks are quietly tightening credit. The mixed signals across private credit mask a single uncomfortable truth.
Alexander Eklund with Rohan Talwar, Oscar McGuinness and Jack Childs7 min read
Partners Group Chair Steffen Meister warns AI will create an asymmetric disaster for private credit, where lenders absorb the losses from disrupted companies while capturing none of the upside.
Rohan Talwar with Oscar McGuinness6 min read
Investors pulled $3.7 billion from the world's largest private credit fund. BCRED has posted its first ever net outflows, signalling a turning point for the entire industry.
Rohan Talwar with Oscar McGuinness5 min read
Blue Owl permanently restricts investors from withdrawing cash from its inaugural retail debt fund, backtracking on plans to reopen redemptions this quarter.
Oscar McGuinness6 min read